Split from Effect of Galantamine Hydrobromide in Chronic Fatigue Syndrome A Randomized Controlled Trial, 2004, Blacker et al.. The quote in this post refers to the Blacker paper. This might also be of interest. It's the main result of an open-label study by Vermeulen et al. published in 2004. They tested the use of acetylcarnitine (ALC), propionylcarnitine (PLC), or a combination of both (ALC + PLC) in a crossover design. At 24 weeks of treatment 59% in the ALC group, 63% in the PLC group, and 37% in the ALC + PLC group reported to be improved. Exploratory open label, randomized study of acetyl- and propionylcarnitine in chronic fatigue syndrome - PubMed (nih.gov) After 24 weeks of therapy, the medication was stopped and all patients returned 2 weeks later for follow-up. As you can see in the table, the % of patients reporting to be improved suddenly dropped to zero.